Guidelines of the spanish society of cardiology. Recomendations for the use of antithrombotic therapy in cardiology;Guías de actuación clínica de la sociedad española de cardiología. Recomendaciones para el uso del tratamiento antitrombótico en cardiología

Revista Espanola de Cardiologia

Volumn 52, Issue 10, 1999, Pages 801-820

  Heras, Magda ^a   Ortiz, Antonio Fernández ^a   Gómez Guindal, José A ^a   Iriarte, José A ^a   Lidón, Rosa María ^a   Gómez, Francisco Pérez ^a   Roldán, Inmaculada ^a  

^a NONE

Author keywords

Acute coronary syndromes; Antithrombotic therapy; Atrial fibrillation; Coronary revascularization; Guidelines; Valvular prostheses

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ANTICOAGULANT THERAPY; CARDIOLOGY; CLINICAL PRACTICE; DEEP VEIN THROMBOSIS; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HUMAN; LUNG EMBOLISM; MEDICAL LITERATURE; MEDICAL SOCIETY; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; REVIEW; RHEUMATIC HEART DISEASE; CORONARY ARTERY DISEASE; EVIDENCE BASED MEDICINE; FIBRINOLYTIC THERAPY; HEART INFARCTION; STANDARD; VEIN THROMBOSIS;

ATRIAL FIBRILLATION; CORONARY DISEASE; EVIDENCE-BASED MEDICINE; HEART VALVE PROSTHESIS; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; THROMBOLYTIC THERAPY; VENOUS THROMBOSIS;

EID: 0033210284     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-8932(99)75009-8     Document Type: Article

References (154)

1. Villar F, Banegas JR, Rodríguez F, Del Rey J. Mortalidad cardiovascular en España y sus comunidades autónomas (1975-1992). Med Clin (Barc) 1998; 110: 321-327.
2. Tomás L. Evolución de la cardiopatía isquémica y de los factores de riesgo en España. Rev Esp Cardiol 1998; 51 (Supl 6): 3-9.
3. Goldstein M. Stroke prevention and health care issues: an American perspective. Cerebrovasc Dis 1993; 3 (Supl 1): 29-33.
4. Schussheim AE, Fuster V. Thrombosis, antithrombotic agents, and the antithrombotic approach in cardiac disease. Prog Cardiovasc Dis 1997; 40: 205-238.
5. Sackett DL, Rosenberg WMC, Gary JAM, Haynes RB, Richardson WS. Evidence based medicine: what is it and what it isn't. Br Med J 1996; 312: 71-72.
6. Sackett DL, Richardson WS, Roseberg W, Haynes RB. Necesity of Evidence-based Medicine. En: Evidence-based Medicine. How to Practice and Teach Evidence-based Medicine. Madrid: Momento Médico Iberoamericano S.L., 1997; 1-17.
7. Haynes RB, Wilczynski NL, McKibbon KA, Walker CJ, Sinclair JC. Developing optimal search strategies for detecting clinically sound studies in MEDLINE. J Am Med Infomr Assoc 1994; 1: 447-458.
8. Richardson WS, Wilson MC, Mishikawa J, Hayward RSA. The well-built clinical question: a key to evidence-based decisions [editorial]. ACP Journal Club 1995; 123: AI2-AI3.
9. Davidoff F, Haynes B, Sackett D, Smith R. Evidence based medicine: a new journal to help doctors identify the information they need. Br Med J 1995; 310: 1.085-1.086.
10. Cochrane Database of Systematic Reviews. Available from Br Med J Publishing Group, PO Box 295. London WC1H 9TE, UK.
11. ACC/AHA Classifying indications for diagnostic and therapeutic procedures. Circulation 1998; 98: 1.949.
12. Clagett GP, Anderson FA, Geerts W, Heit JA, Knudson M, Lieberman JR et al. Prevention of venous thromboembolism. Chest 1998; 114: (Supl): 531-560.
13. Eriksson BI, Ekman S, Linbratt S, Baur M, Bach D, Trholm C et al. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (revasc) with that of unfractioned heparin in patients having a total hip replacement. J Bone Joint Surg 1997; 79A: 326-333.
14. Eriksson BI, Ekman S, Kálebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with rccombinant hirudin, CGP 39393. Lancet 1996; 347: 635-639.
15. Dahl OE, Andreassen G, Aspelin P, Muller C, Mathiesen P, Nyhus S et al. Prolonged thromboprophylaxis following hip replacement surgery. Results of a double blind, prospective randomized, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost 1997; 77: 26-31.
16. Hull RD, Pineo GF. Prophylaxis of deep venous thrombosis and pulmonary embolism. Current recommendations. Med Clin North Am 1998; 82: 477-493.
17. Bick RL, Haas SK. International consensus recommendations. Summary statement and additional suggested guidelines. Med Clin North Am 1998; 82: 613-633.
18. Palmer AJ, Schramm W, Kirchhof B, Bergemann R. Low molecular weight heparin and unfractionated heparin for prevention of thrombo-embolism in general surgery: a meta-analysis of randomised clinical trials. Haemostasis 1997; 27: 65-74.
19. Bergmann JF, Elkharrat D. Prevention of venous thromboembolic risk in non-surgical patients. Haemostasis 1996; 26 (Supl 2): 16-23.
20. Bergmann JF, Neuhart E. A multicenter randomized doubleblind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. Thromb Haemost 1996; 76: 529-534.
21. Kakkar VV. Effectiveness and safety of low molecular weight heparins (LMWH) in the prevention of venous thromboembolism (VTE). Thromb Haemost 1995; 74: 364-368.
22. Acar J, Iung B, Boissel JP, Samama MM, Michel PL, Teppe JP et al. AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation 1996; 94: 2.107-2.112.
23. Eric Jamieson WR, Miyagishima RT, Tyers FO, Lichenstein SV, Ian Munro A, Burr LH. Bileaflet mechanical prostheses in mitral and multiple valve replacement surgery. Influence of anticoagulant management on performance. Circulation 1997; 96 (Supl 2): 134-140.
24. Cannegieter SC, Rosendaal FR, Wintzen AR, Van der Meer FJM, Vandenbroucke JP, Briët E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-17.
25. Stein PD, Alpert JS, Dalen JE, Horstkotte D, Turpie AGG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1998; 114 (Supl): 602-610.
26. Bonow RO, Carabello B, De Leon AC, Edmuns LH, Fedderly BJ, Freed MD et al. Guidelines for the management of patients with valvular heart disease. Circulation 1998; 98: 1.949-1.984.
27. Stein PD, Alpert JS, Copeland J, Dalen JE, Goldman S, Turpie AGG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1995; 108 (Supl): 371-379 (fe de errores en Chest 1996; 109: 592).
28. Stein PD, Alpert JS, Copeland J, Dalen JE, Goldman S, Turpie AGG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1995; 108 (Supl): 371-379 (fe de errores en Chest 1996; 109: 592).
29. Meschengieser SS, Fondevila CG, Frontroth J, Santarelli MT, Lazzari MA. Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: a randomized trial in patients with mechanical prosthetic heart valves. J Thorac Cardiovasc Surg 1997; 113: 910-916.
30. Altman R, Rouvier J, Gurfinkel E, Scazziota A, Turpie AGG. Comparison of high-dose with low-dose aspirin in patients with mechanical heart valve replacement treated with oral anticoagulant. Circulation 1996; 94: 2.113-2.1 16.
31. Cappelleri JC, Fiore LD, Brophy MT, Deykin D, Lau J. Efficacy and safety of combined anticoagulant and antiplatelet therapy versus anticoagulant monotherapy after mechanical heart-valve replacement: a metaanalysis. Am Heart J 1995; 130: 547-552.
32. Gohlke-Bärwolf C, Acar J, Burckhardt D, Oakley C, Butchart E, Krayenbühl P et al. Guidelines for prevention of thromboembolic events in vulvulur heart disease. Eur Heart J 1995; 16: 1.320-1.330.
33. Tiede DJ, Nishimura RA, Gastineau DA, Mullany CJ, Orszulak TA, Schaff H V. Modern management of prosthetic valve anticoagulation. Mayo Clin Proc 1998; 73: 665-680.
34. Altman R, Rouvier J, Gurfinkel E. Oral anticoagulant treatment with and without aspirin. Thromb Haemost 1995; 74: 506-510.
35. Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR et al. High risk of thromboembolism early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 1995; 25: 1.111-1.119.
36. Lengyel M, Fuster V, Keltai M, Roudaut R, Schulte HD, Seward JB et al. Guidelines for the management of left-sided prosthetic valve thrombosis: a role for thrombolytic therapy. J Am Coll Cardol 1997; 30: 1.521-1.526.
37. Manteiga R, Souto JC, Altès A, Mateo J, Arís A, Domínguez JM et al. Short-course thrombolysis as the first line of therapy for cardiac valve thrombosis. J Thorac Cardiovasc Surg 1998; 115: 780-784.
38. Renzulli A, Vitale N, Caruso A, Dialetto G, De Luca Tupputi Schinosa L, Cotrufo M. Thrombolysis for prosthetic valve thrombosis: indications and results. J Heart Valve Dis 1997; 6: 212-218.
39. Lécuru F, Desnos M, Taurelle R. Anticoagulant therapy in pregnancy. Report of 54 cases. Acta Obstet Gynecol Scand 1996; 75: 217-221.
40. Sbarouni E, Oakley CM. Outcome of pregnancy in women with valve prosthesis. Br Heart J 1994; 71: 196-201.
41. Ginsberg JS, Hirsch J. Use of antithrombotic agents during pregnancy. Chest 1998; 114 (Supl): 524-530.
42. Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE. The Evolving Consensus. Antithrombotic therapy in Atrial Fibrillation. Chest 1998; 114: 579-589.
43. Nademanee K, Kosar EM. Long-term antithrombotic treatment for atrial fibrillation. Am J Cardiol 1998; 82: 37N-42N.
44. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1.449-1.457.
45. Wolf Ph A, Dawher ThR, Thomas HE, Kannel WB. Epidemiologic assesment of chronic atrial fibrillation and risk of stroke: The Framingham Study. Neurology 1978; 28: 973-977.
46. Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR Jr, Ilstrup DM et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 1987; 317: 669-674.
47. Petersen P, Boisen G, Godtfredsen J, Anderson ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenghagen AFASAK study. Lancet 1989; 1: 175-179.
48. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990; 323: 1.505-1.511.
49. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: Final results. Circulation 1991; 84:527 539.
50. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC et al. for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevent on of stroke associated with non-rheumatic atrial fibrillation. N Engl J Med 1992; 327: 1.406-1.412.
51. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention ol thromboembolism in atrial fibri-llation. Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687-691.
52. Van Latum JC, Koudstaal PJ, Venables GS, Van Gijn J, Kapelle LJ, Algra A. for the European Atrial Fibrillation Trial (EAFT) Study Group. Predictors of Major Vascular Events in Patients with a Transient Ischemic Attack or Minor Ischemic Stroke and with Nonrheumatic Atrial Fibrillation. Lancet 1993; 342: 1.255-1.262.
53. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian atrial fibrillation anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18: 349-355.
54. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted dose warfarin versus low intensity, fixed dose warfarin plus aspirin for high risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation III randomized clinical trial. Lancet 1996; 348:633-638.
55. Weigner MJ, Caulfield TA, Danias PG, Silverman DI, Manning WJ. Risk of clinical thromboembolism associated with cardioversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med 1997; 126: 615-620.
56. Golzari H, Cebul RD, Bahler RC. Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy. Ann Intern Med 1996; 125: 311-323.
57. Manning WJ, Silverman DI, Gordon SPF, Krumholz HM, Douglas PS. Cardioversion from atrial fibrillation without prolonged anticoagulation with use of TEE to exclude the presence of atrial thrombi. N Engl J Med 1993; 328: 750-755.
58. Fuster V, Gersh BI, Guiliani ER, Tajik AJ, Brandenburg RO, Frye RL. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981; 47: 525-531.
59. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Conn JN. Incidence of thromboembolic events in congestive heart failure. Circulation 1993; 87 (Supl 6): 94-101.
60. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669-677.
61. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325: 293-302.
62. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992: 327: 685-691.
63. Dries DL, Rosenberg Y, Waclawiw M, Domanski M. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol 1997; 29: 1.074-1.080.
64. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986; 314: 1.547-1.552.
65. Cohn JN, Johnson G, Ziesche S. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310.
66. Loh E, Sutton MS, Wun CC, Rouleau JL, Flaker GC, Gottlieb SS et al. Ventricular dysfunction predicts stroke following myocardial infarction. N Engl J Med 1997; 336: 251-257.
67. Dries DL, Domanski M, Waclawiw M, Gersh B. Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure. Am J Cardiol 1997; 79: 909-913.
68. Koniaris LS, Goldhaber SZ, Anticoagulation in dilated cardiomyopathy. J Am Coll Cardiol 1998; 31: 7.
69. Ambrose JA, Hjemdahl-Monsen CE, Borrico S, Gorlin R, Fuster V. Angiographic demonstration of a common link between unstable angina pectoris and non-Q wave acute myocardial infarction. Am J Cardiol 1988; 61: 244-247.
70. Antiplalelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I. Prevention of death, myocardial infacrtion, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106 [fe de errores. Br Med J 1994; 308: 1.540].
71. Antiplalelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I. Prevention of death, myocardial infacrtion, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106 [fe de errores. Br Med J 1994; 308: 1.540].
72. Lewis HD, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309: 396-403.
73. Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA et al. Aspirin, sulfinpyrazone or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med 1985; 313: 1.369-1.375.
74. Cohen M. New therapies for unstable angina and non-Q-wave myocardial infarction: recent clinical trials. Am Heart J 1998; 135 (Supl): 343-352.
75. Plaza L, López Bescos L, Martín Jadraque L, Alegría E, Cruz Ferńandez JM, Velasco J et al. Protective effect of triflusul against acute myocardial infarction in patients with unstable angina: results of a Spanish multicenter trial. Cardiology 1993; 82: 388-398.
76. Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F et al. for Studio della ticlopidina nell Angina Instabile Group. Antiplatelet treatment with ticlopidine in Unstable Angina: a controlled multicenter clinical trial. Circulation 1990; 82: 17-26.
77. PRISM-PLUS Study Investigators. Inhibition of the Platelet Glycoprotein IIb-IIIa Receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998; 338: 1.488-1.497.
78. PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1.498-1.505.
79. The PURSUIT Trial Investigators. Inhibition of Platelet Glycoprotein IIb-IIIa with eptifibatide in patients with acute coronary syndroms. N Engl J Med 1998; 339: 436-143.
80. The PARAGON Trial Investigators. International Randomized Controlled Trial of Lamifiban (a Platelet Glycoprotein IIb-IIIa Inhibitor). Heparin or both in Unstable Angina. Circulation 1998; 97: 2.386-2.395.
81. Theroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1.105-1.111.
82. Cohen M, Demers C, Gurfinkel EP, Goodman S, Langer A, Califf RM et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease: efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary Events Study Group. N Engl J Med 1997; 337: 447-452.
83. López-Sendón J, Antman EM, McCabe CH, Gurfinkel E, Turpie AG, Fox KM et al. for the TIMI-11B Investigators. Superiority of enoxaparin over unfractioned heparin in unstable angina occurs early in treatment: results from TIMI-11B. J Am Coll Cardiol 1999; 33: 352A.
84. Fragmin During Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561-568.
85. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AG et al. Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study). Fragmin in Unstable Coronary Disease. Am J Cardiol 1997; 80: 30-34.
86. Gurfinkel EP, Manos EJ, Mejail IR, Cerda MA, Duronto EA, Garcia CN et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995; 26: 313-318.
87. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775-782.
88. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR et al. Treatment with bivalidurin (hirulog) as compared heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995; 333: 764-769.
89. Organisation to Assess Estrategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischemia without ST elevation: a randomized trial. Lancet 1999; 353: 429-438.
90. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-360.
91. O'Connor CM, Meese RB, McNulty S, Lucas KD, Carney RJ, LeBoeuf RM et al, for the DUCCS-II Investigators. A randomised factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. Am J Cardiol 1996; 77: 791-797.
92. Roux S, Christeller S, Ludin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol 1992; 19: 671-677.
93. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1.329-1.339.
94. Ohman EM, Kleiman NS, Gaicoch G, Worley SJ, Navetta FI, Talley D et al. for the IMPACT-AMI Investigators. Combined accelererated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrelin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. Circulation 1997; 95: 846-854.
95. The PARADIGM Investigators. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor Lamifiban: Results of the Platelet Agregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Trial. J Am Coll Cardiol 1998; 32: 2.003-2.010.
96. Giugliano AP, Antman EM, McCabe CH, Anderson KM, Adgey AAJ, Kleiman NS et al. Abciximab + tPA improves coronary flow in a wide range of subgroups. Results from TIMI 14. Circulation 1998; 98 (Supl 1): 560.
97. Mahaffey KW, Granger CB, Collins R, O'Connor M, Ohman M, Bleich SD et al. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol 1996; 77: 551-556.
98. Granger CB, Hirsh J, Califf RM, Col J, White HD, Betriu A et al, for the GUSTO-I Trial Investigators. Activeted partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I Trial. Circulation 1996; 93: 870-878.
99. Granger CB, Beecker R, Tracy RP, Califf RM, Topol EJ, Pieper KS et al, for the GUSTO-I Hemostasis Substudy Group. Thrombin generation, inhibition and clinical outcome in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I trial. J Am Coll Cardiol 1998; 31: 497-505.
100. White HD. Is heparin of value in the management of acute myocardial infarction? Cardiovasc Drugs Ther 1997; 11: 111-119.
101. French JK, White HD. Adjunctive antithrombotic therapy for acute myocardial infarction. En: Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ, editores. Evidence based cardiology. Londres: Churchill Livingstone. 1998; 460-478.
102. Cairns JA, Kennedy JW, Fuster V. Coronary thrombolysis. Chest 1998; 114 (Supl): 634-657.
103. Antman EM, for the TIMI 9B Investigators. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial. Circulation 1996; 94: 90; 1.631-1.637.
104. Théroux P, Pérez-Villa F, Waters D, Lespêrance J, Shabani F, Bonan R. Randomized double-blind comparison of two doses of Hirulog with Heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995; 91: 2.132-2.139.
105. White HD, Aylward BM, Frey MS, Adgey AAJ, Nair R, Hillis WS et al, on behalf of the Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Randomized, double-blind comparison of Hirulog versus Heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997; 96: 2.155-2.161.
106. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 2: oral anticoagulants. Circulation 1994; 89: 1.469-1.480.
107. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147-152.
108. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research group. Effect of longterm oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994; 343: 499-503.
109. Meijer A, Verneught FWA, Werter CJPJ, Lie KI, Van der Pol JMJ, Van Eenige MJ. Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographiic study: results of the APRICOT Study. Circulation 1993; 87: 1.524-1.530.
110. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomized double-blinded of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997; 350: 389-396.
111. Cairns JA, Théroux P, Leais HD, Ezckowitz M, Meade TW, Sutton GC. Antithrombotic agents in coronary artery disease. Chest 1998; 114 (Supl): 611-633.
112. Barnathan ES, Schwartz JS, Taylor L, Laskey WK, Kleaveland JP, Kussmaul WG et al. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 1987; 76: 125-134.
113. The EPIC Invtstigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961.
114. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1.429-1.435.
115. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Eng J Med 1997; 336: 1.689-1.696.
116. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1.445-1.453.
117. The IMPACT II Investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention. Lancet 1997; 349: 1.422-1.428.
118. Boccara A, Benamer H, Juliard JM, Aubry P, Goy P, Himbert D et al. A randomized trial of a fixed high dose vs a weight-adjusted low dose of intravenous heparin during coronary angioplasty. Eur Heart J 1997; 4: 631-635.
119. Serruys PW, Herrman JP, Simon R, Rutsch W, Bode C, Laarman GJ et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med 1995; 333: 757-763.
120. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable and postinfarction angina Hirulog Angioplasty Study Investigators. N Engl J Med 1995; 333: 764-769.
121. Schachinger V, Kasper W, Zeiher AM. Adjunctive intracoronary urokinase therapy during percutaneous transluminal coronary angioplas y. Am J Cardiol 1996; 77: 1.174-1.178.
122. Schömig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Eng J Med 1996; 334: 1.084-1.089.
123. Schühlen H, Hadamitzky M, Walter H, Ulm K, Schömig A. Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a Prospective Risk Stratification Protocol in the Intracoronary stenting and Antithrombotic Regimen (ISAR) Trial. Circulation 1997; 95: 2.015-2.021.
124. Urban P, Macaya C, Rupprecht HJ, Kiemeneij F, Emanuelsson H, Fontanelli A et al. for the MATTIS Investigators. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients. Circulation 1998; 98: 2.126-2.132.
125. Bertrand M, Legrand V, Boland T, Fleck E, Bonnier J, Emmanuelson H et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlipidine (FANTASTIC) Study. Circulation 1998; 98: 1.597-1.603.
126. Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, Martini G et al. Intracoronary stenting without anticoagulation accomplished with intravascular untrasound guidance. Circulation 1995; 91: 1.676-1.688.
127. Karillon GJ, Maurice MC, Benveniste E, Bunouf P, Aubry P, Cattan S et al. Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy: 30-day clinical outcome of the French Multicenter Registry. Circulation 1996; 94: 1.519-1.527.
128. Zubaid M, Penn IM, Buller CE, Moscovich MD, Ricci DR, Chauhan A. Antiplatelet therapy alone is safe and effective after coronary stenting: observation of a transition in practice. Can J Cardiol 1997; 13: 335-340.
129. Hall P, Nakamura S, Maiello L, Itoh A, Blengino S, Martini G et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996; 93: 215-222.
130. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998; 339: 1.665-1.671.
131. The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352: 87-92.
132. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343: 881-886.
133. Faxon DP, Spiro TE, Minor S, Cote G, Douglas J, Gottlieb R et al. Low molecular weight heparin in prevention of restenosis after angioplasty: result of the enoxaparin restenosis (ERA) trial. Circulation 1994; 90: 908-914.
134. Cairns JA, Gill J, Morton B, Roberts R, Gent M, Hirsh J et al. Fish oils and low-molecular -weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty: the EMPAR Study. Circulation 1996; 94: 1.553-1.560.
135. Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ et al. Low molecular weight heparin (Reviparin) in percutaneous transluminal coronary angioplasty: results of a randomized, double-blind, unfractioned heparin and placebo-controlled, multicenter trial (REDUCE Trial). J Am Coll Cardiol 1996; 28: 1.437-1.443.
136. Lablanche JM, McFadden EP, Meneveau N, Lusson JR, Bertrand B, Metzger JP et al. Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: The FACT Study. Circulation 1997; 96: 3.396-3.402.
137. Urban P, Buller N, Fox K, Shapiro L, Bayliss J, Rickards A. Lack of effect of warfarin on the restenosis rate on clinical outcome after balloon coronary angioplasty. Br Heart J 1988; 60: 485-488.
138. Kastrati A, Schühlen H, Hausleiter J, Walter H, Zitzmann-Roth E, Hadamitzky M et al. Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the intracoronary stenting and antithrombotic regimen (ISAR) trial. Circulation 1997; 96: 462-467.
139. Stein PD, Dalen JE, Goldman S, Théroux P. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. Chest 1998; 114 (Supl): 658-665.
140. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of agressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous -vein coronary-artery bypass grafts. N Engl J Med 1997; 336: 153-162.
141. Iriarte JA, De Gandarias JM. Antiagregantes plaquetarios. En: Iriarte JA, Prada O. editores. Tratamiento anticoagulante oral. Madrid: Sociedud Española de Cardiología, 1992; 423-435 y 439-449.
142. Holbrook AM, Wells PS, Crowther NR. Pharmacokinetics and drug interactions with warfarin. En: Poller L. Hirsh J, editores. Oral Anticoagulants. Londres: Arnold. 1997; 3: 30-48.
143. Heras M, Pérez F, Roldán I, Iriarte JA. Indicaciones actuales de los antiagregantes y anticoagulantes en cardiología. En: Normas de actuación clínica en cardiología. Madrid: Sociedad Española de Cardología, 1995; 407-414.
144. Fernández MA. Dificultades de manejo de los anticoagulantes orales. Interacciones farmacológicas y resistencias. Valencia: Simposium Internacional sobre la Utilización de los Anticoagulantes en Europa, noviembre de 1993.
145. Iriarte JA, Molinero E. I Jornadas sobre control del tratamiento anticoagulante en las diferentes Comunidades Autónomas. Bilbao: Comisión de Tromboembolismo y de Docencia del Hospital de Basurto, noviembre de 1996.
146. De Moerloose P. Anticoagulated patients: importance of the educational aspects. Haemostatis 1998; 28 (Supl 2): 287.
147. Terént A. Incorrectly titred anticoagulant therapy is expensive. Could self-monitoring improve the situation? Läkartidningen 1998; 95: 2.223-2.238.
148. Quick AJ. The prothrombine time in haemophilia and in obstructive jaundice. J Biol Chem 1935; 109: 73-74.
149. Poller L, Van den Besselaar AMHP, Jespersen J, Tripodi A, Houghton D. A comparison of artificially-depleted, lyophilized coumarin and fresh coumarin plasmas in thromboplastin calibration. Br J Haematol 1998; 101: 462-467.
150. Poller L, Van den Besselaar AMHP, Jespersen J, Tripodi A, Houghton D. A comparison of linear and orthogonal regression analysis for local INR determination in ECAA coagulometer studies. Br J Haematol 1998; 102: 910-917.
151. Vacas M, Lafuente PJ, Aguirrebeitia MJ, Iriarte JA. Evaluación de la calidad de la técnica del tiempo de protrombina en el País Vasco. Sangre 1998; 43: 41-45.
152. Coller BS, Lang D, Scudder LE. Rapid and simple platelet function assy to asses glycoprotein IIb/IIIa receptor blockade. Circulation 1997; 95: 860-867.
153. Smith JW, Steinhubl SR, Lincoff AM, Coleman JC, Lee TT, Hillman RS et al. Rapid platelet-function assay. An automated and quantitative cartridge-based method. Circulation 1999; 99: 620-625.
154. Pinton P. Abciximab-induced thrombocitopenia in the treatment of acute coronary syndromes by angioplasty. Ann Cardiol Angiol 1998; 47: 351-358.